Homeemc易倍官网入口Newsroom – Press Releases emc易倍官网入口 emc易倍官网入口 Filter Topics Corporate Financial Neuroscience News Oncology Partnering Rare Diseases Research Sustainability Period 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 Filter by X recent search Reset Showing: 1 – 5 of 257 Press Releases Show 05 10 20 30 40 50 Sort Descending Ascending 21 August 2026 21 August 2026 Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline 30 July 2026 30 July 2026 Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance 4 related documents/links H1 2026 – Results Announcement (707.30 KB) H1 2026 – Results Highlights (191.92 KB) H1 2026 – Investor Presentation (1.93 MB) H1 2026 – Results Webcast Replay 29 July 2026 29 July 2026 Ipsen nominates Catherine Bradley to its Board of Directors as independent Director 24 July 2026 24 July 2026 Ipsen provides update on Phase III BOLD trial in biliary atresia 22 July 2026 22 July 2026 Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline 12…52 Your dedicated contacts Sally Bain Head of Global Media Relations +1 857 320 0517 emc易倍官网入口sally.bain@ipsen.com Anne Liontas France Media Relations +33 7 67 34 72 96 anne.liontas.ext@ipsen.com Stay updated Register to receive our latest news